The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach ; volume:37 ; number:7 ; day:22 ; month:5 ; year:2020 ; pages:3246-3264 ; date:7.2020
Advances in therapy ; 37, Heft 7 (22.5.2020), 3246-3264, 7.2020
- Urheber
-
Wuyts, Wim A.
Papiris, Spyridon
Manali, Effrosyni
Kilpeläinen, Maritta
Davidsen, Jesper Rømhild
Miedema, Jelle
Robalo-Cordeiro, Carlos
Morais, Antonio
Artés, Maite
Asijee, Guus
Cendoya, David
Soulard, Stéphane
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-020-01384-0
- URN
-
urn:nbn:de:101:1-2020082101121457154867
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wuyts, Wim A.
- Papiris, Spyridon
- Manali, Effrosyni
- Kilpeläinen, Maritta
- Davidsen, Jesper Rømhild
- Miedema, Jelle
- Robalo-Cordeiro, Carlos
- Morais, Antonio
- Artés, Maite
- Asijee, Guus
- Cendoya, David
- Soulard, Stéphane
- SpringerLink (Online service)
Ähnliche Objekte (12)
The natural history of progressive fibrosing interstitial lung diseases
Progressive fibrosing interstitial lung disease: prevalence and clinical outcome
Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study)
Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review
Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study
Screening for rheumatoid arthritis-associated interstitial lung disease—a Delphi-based consensus statement
Lung CCR6−CXCR3− type 2 helper T cells as an indicator of progressive fibrosing interstitial lung diseases
Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
MDA-5 associated rapidly progressive interstitial lung disease with recurrent Pneumothoraces: a case report
Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome
The natural history of progressive fibrosing interstitial lung diseases
Progressive fibrosing interstitial lung disease: prevalence and clinical outcome
Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study)
Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review
Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study
Screening for rheumatoid arthritis-associated interstitial lung disease—a Delphi-based consensus statement
Lung CCR6−CXCR3− type 2 helper T cells as an indicator of progressive fibrosing interstitial lung diseases
Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
MDA-5 associated rapidly progressive interstitial lung disease with recurrent Pneumothoraces: a case report
Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome
The natural history of progressive fibrosing interstitial lung diseases
Progressive fibrosing interstitial lung disease: prevalence and clinical outcome
Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study)
Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review
Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study
Screening for rheumatoid arthritis-associated interstitial lung disease—a Delphi-based consensus statement
Lung CCR6−CXCR3− type 2 helper T cells as an indicator of progressive fibrosing interstitial lung diseases
Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
MDA-5 associated rapidly progressive interstitial lung disease with recurrent Pneumothoraces: a case report